Gene Therapy for Inherited Retinal Diseases
Understanding Gene Therapy for the Retina
Gene therapy is a medical approach in which new, functional genes are delivered into a patient's cells. These new genes replace genes that are missing or not working correctly. In retinal gene therapy, the goal is to provide retinal cells with a healthy copy of the gene responsible for a specific inherited condition. This can help cells function more normally and, in some cases, improve vision.
The eye is especially well suited for gene therapy. It is small, so relatively low doses of the therapy can reach the target cells. The eye is also considered immune-privileged. This means the body is less likely to reject new material delivered there compared to other organs.
A specially prepared virus, most commonly an adeno-associated virus (AAV), carries the healthy gene into retinal cells. AAV vectors do not cause disease in humans and are engineered to deliver genetic material safely. Depending on the therapy, the gene may be injected beneath the retina during a vitrectomy (surgery to remove the gel inside the eye). Other approaches use an intravitreal injection (an injection into the gel-filled space of the eye). A suprachoroidal injection (delivery behind the retina through an in-office procedure) is another option.
Inherited retinal diseases affect specific cell types in the retina. Researchers have identified the exact gene mutations responsible for many of these conditions. They can design therapies that target the right cells with the right genetic correction. Over 260 disease-causing genes for inherited retinal diseases have been identified, creating many potential therapeutic targets. The contained environment of the eye also makes it easier to measure treatment effects and monitor safety.
Who Is Affected and Risk Factors
Inherited retinal diseases (IRDs) affect approximately 1 in 2,000 people worldwide, impacting more than two million individuals globally. These conditions are the leading cause of blindness among working-age adults in Western countries. Retinitis pigmentosa, one of the most common inherited retinal diseases, has an estimated prevalence of 1 in 3,000 to 7,000 individuals (Frontiers in Medicine, 2021).
Inherited retinal diseases can follow several genetic inheritance patterns. These include autosomal dominant, autosomal recessive, and X-linked inheritance. Maternal (mitochondrial) inheritance is very rare. X-linked retinoschisis, the most common form of juvenile-onset retinal degeneration in males, has an estimated prevalence of 1 in 15,000 to 30,000.
Certain populations may have a higher prevalence of inherited retinal diseases. Communities where marriages between close relatives are more common tend to see higher rates of autosomal recessive conditions.
Many different genes can cause inherited retinal diseases. For retinitis pigmentosa alone, 87 individual disease-causing genes have been identified. Three genes account for roughly a substantial proportion of all retinitis pigmentosa cases: RHO, USH2A, and RPGR (RetNet, NEI). Mutations in the RPE65 gene are responsible for certain forms of Leber congenital amaurosis (a severe childhood-onset retinal disease) and some types of retinitis pigmentosa. Biallelic (two-copy) RPE65 mutations account for 3 to 16 percent of Leber congenital amaurosis cases.
Signs and Symptoms
Some inherited retinal diseases appear very early in life. Leber congenital amaurosis (LCA) is usually detected when children show profound visual impairment in infancy. Parents may notice their child does not fix their gaze on objects or follow moving objects. Eye rubbing is another common sign. The rubbing stimulates photoreceptor cells and creates brief sensations of light.
In retinitis pigmentosa, the earliest symptom is often night blindness, meaning difficulty seeing in dim light. Patients may also struggle to adapt when moving between bright and dark environments. Over time, the visual field begins to narrow, typically starting from the mid-periphery. It gradually closes inward, sometimes described as tunnel vision.
One form of Leber congenital amaurosis caused by RPE65 gene mutations usually affects night vision first. Children and young adults with this form may have particular difficulty navigating in dimly lit rooms.
Most inherited retinal diseases are progressive, meaning vision worsens over months to years. The rate of progression varies widely depending on the specific gene involved and the individual patient. Some people retain useful central vision for many years, while others experience more rapid decline. Because the changes can be gradual, patients may not notice early vision loss without specialized testing.
Diagnosis and Testing
A retina specialist can identify signs of inherited retinal diseases during a comprehensive dilated eye exam. The retina may show characteristic changes such as bone spicule pigment deposits (dark spots shaped like bone fragments), thinning of the retinal layers, or pale optic nerves. These findings, combined with a patient's symptoms and family history, help guide the diagnosis.
Several tests help confirm the diagnosis and assess how much retinal function remains. These may include:
- Optical coherence tomography (OCT), which creates detailed cross-sectional images of the retina
- Electroretinography (ERG), which measures the electrical activity of retinal cells in response to light
- Visual field testing, which maps the areas of remaining vision
- Fundus autofluorescence imaging, which reveals patterns of retinal cell health and damage
Genetic testing is a critical step for patients with suspected inherited retinal diseases. A blood sample or cheek swab can identify the specific gene mutation responsible for the condition. This information determines whether a patient may be eligible for an existing gene therapy or a clinical trial. Genetic counseling is often recommended to help patients and families understand the results, inheritance risks, and available options.
Treatment Options
Luxturna (voretigene neparvovec) became the first FDA-approved gene therapy for a genetic disease when it received approval on December 17, 2017. It is designed for patients with vision loss caused by biallelic (two-copy) mutations in the RPE65 gene. Approximately 1,000 to 3,000 patients in the United States have this specific form of retinal dystrophy (FDA, 2017).
Luxturna is delivered through a subretinal injection during a vitrectomy procedure. A retina specialist injects the therapy beneath the retina, allowing the healthy RPE65 gene to enter the appropriate cells. Each eye is treated in a separate surgical session. The treatment aims to improve the ability of retinal cells to produce a protein essential for the visual cycle, particularly for vision in low light.
In March 2025, the FDA approved Encelto (revakinagene taroretcel), an encapsulated cell-based gene therapy for adults with idiopathic macular telangiectasia type 2. This therapy is administered into the eye during a single surgical procedure. It works by continuously producing a protective protein called ciliary neurotrophic factor (CNTF) to support retinal cells affected by the condition.
Optogenetics is a newer strategy being explored for patients who have already lost most of their photoreceptor cells. This approach uses a one-time intravitreal injection to deliver light-sensing molecules to surviving retinal cells. These cells are essentially reprogrammed to detect light, replacing the function of lost photoreceptors. GenSight Therapeutics is testing an optogenetic therapy that combines an eye injection with high-tech goggles that enhance light signals to the treated cells.
More than three dozen retinal gene therapy clinical trials are currently in progress. Over 100 clinical trials targeting inherited retinal diseases have been documented through the end of 2022. Research strategies include gene augmentation (adding a working gene), gene editing (correcting the mutation directly), and delivery of protective molecules. Notable programs include:
- Three companies, including Meira GTX, Applied Genetic Technologies, and BioGen, are developing gene therapies for X-linked retinitis pigmentosa caused by RPGR mutations
- 4D Molecular Therapeutics is testing a gene therapy that does not require vitrectomy surgery
- ProQR Therapeutics is developing a therapy for vision loss caused by USH2A mutations, which affect patients with retinitis pigmentosa and Usher syndrome
- The AAVIATE trial is evaluating RGX-314, which has shown promising results while reducing the number of injections needed
New research on MCO-010, an optogenetic gene therapy, suggests it can improve vision in people with retinitis pigmentosa who have lost nearly all sight. In clinical testing, up to 50 percent of treated patients gained three lines of vision on a standard eye chart. Researchers believe this approach could also help patients with other types of retinal degeneration beyond retinitis pigmentosa.
What to Expect
Patients considering gene therapy will undergo thorough evaluation. This includes genetic testing to confirm the specific mutation, detailed retinal imaging, and functional vision testing. A retina specialist will review whether enough viable retinal cells remain for the therapy to be effective. Genetic counseling may also be part of the process. For therapies like Luxturna, both eyes are not treated at the same time. Sessions are scheduled weeks apart to monitor the first eye before treating the second.
For subretinal gene therapies like Luxturna, the procedure involves a vitrectomy. The retina specialist removes the vitreous gel and carefully injects the gene therapy solution beneath the retina. The surgery is performed under anesthesia. For intravitreal gene therapies, the injection is delivered into the vitreous cavity in a manner similar to other eye injections, though often in an operating room setting. Suprachoroidal delivery is a newer approach that may be performed in an office setting. Initial studies suggest it is relatively safe and well tolerated.
Recovery after subretinal gene therapy typically involves several weeks of restricted activity. Patients may need to maintain specific head positions to support healing. Multiple follow-up visits with a retina specialist are required to monitor the retina and assess visual improvement. Results are not immediate. Vision improvements, when they occur, may develop gradually over weeks to months. Not all patients experience the same degree of benefit. Outcomes depend on factors including the amount of remaining retinal function at the time of treatment.
Living with an Inherited Retinal Disease
Many patients with inherited retinal diseases live with progressive vision changes for years before and after any treatment. Practical adaptations can help maintain independence. These may include using magnifying devices, improving lighting at home, learning orientation and mobility skills, and working with low vision rehabilitation specialists. Support groups and patient advocacy organizations can also provide valuable resources and community connection.
Even if no approved gene therapy exists for a specific mutation today, genetic testing remains important. Knowing the exact genetic cause helps patients understand their condition and informs family planning decisions. It may also qualify patients for clinical trials. The field of retinal gene therapy is advancing rapidly, and new therapies are entering clinical testing each year. A retina specialist or genetic counselor can help patients stay informed about relevant developments.
Receiving a diagnosis of an inherited retinal disease carries significant emotional weight. This is especially true for parents learning their child has a condition that may cause progressive vision loss. Feelings of grief, anxiety, and uncertainty are normal. Connecting with mental health professionals experienced in chronic illness can provide meaningful support. Patient communities are another valuable resource. Honest conversations with a retina specialist about realistic expectations for current and future treatments can also help patients and families navigate the path forward.
When to See a Retina Specialist
Any unexplained difficulty with night vision, narrowing of the visual field, or progressive vision loss should prompt evaluation by a retina specialist. Parents who notice that their child does not fix their gaze, does not follow moving objects, or frequently rubs their eyes should seek a prompt referral. Early diagnosis allows for timely genetic testing and consideration of available treatments or clinical trials.
While inherited retinal diseases are typically progressive rather than sudden, any abrupt change in vision requires immediate attention. A sudden increase in floaters, flashes of light, a curtain or shadow over part of the vision, or sudden vision loss in one eye are emergencies. See a retina specialist or go to the emergency room immediately if any of these symptoms occur. They may indicate a separate condition such as a retinal detachment that needs urgent treatment.
Questions and Answers
Not yet. Luxturna (voretigene neparvovec) is currently the only FDA-approved gene therapy specifically for an inherited retinal disease. It treats only those caused by biallelic RPE65 mutations. However, more than three dozen clinical trials are in progress targeting various genetic mutations and conditions. A retina specialist can help determine whether a patient's specific mutation is being studied in a clinical trial.
The first step is genetic testing to identify the specific gene mutation causing your condition. A retina specialist or genetic counselor can order this testing and interpret the results. Once the mutation is known, they can search clinical trial databases for studies that match your genetic profile. They will also assess whether you meet the eligibility criteria based on your remaining vision and retinal health.
Gene therapy works best when enough healthy retinal cells remain to respond to the treatment. It cannot regenerate cells that have already been destroyed. In patients with sufficient remaining retinal function, gene therapy may improve certain aspects of vision, particularly in low-light conditions. However, results vary from person to person. Gene therapy should not be expected to restore vision to normal levels. Early diagnosis and timely treatment offer the best opportunity for meaningful benefit.
Gene augmentation delivers a working copy of a defective gene to the cells that need it. This approach works for patients who still have viable photoreceptor cells that can benefit from the corrected gene. Optogenetics takes a different approach by reprogramming surviving retinal cells that are not normally light-sensitive to detect light. This strategy is designed for patients who have already lost most or all of their photoreceptors and may have very limited remaining vision.
Genetic testing for family members can be valuable. It can identify carriers who may not show symptoms but could pass the condition to their children. It also helps identify relatives who may be in the early stages of the same condition before significant vision loss occurs. A genetic counselor can guide families through the testing process, explain inheritance patterns, and discuss what the results mean for each family member.